News & Updates

Marstacimab trumps FRT for severe haemophilia without inhibitors

28 Dec 2023 by

The novel, investigational anti-tissue factor pathway inhibitor marstacimab outdid factor replacement therapy (FRT) in reducing bleeds in patients with severe haemophilia A (HA) or moderately severe to severe haemophilia B (HB) without inhibitors beyond 12 months in the phase III BASIS trial.

Marstacimab trumps FRT for severe haemophilia without inhibitors

28 Dec 2023

Risankizumab superior to ustekinumab in severe CD

27 Dec 2023 by

Risankizumab outdoes ustekinumab in achieving endoscopic remission at week 24 in patients with moderate-to-severe Crohn’s disease (CD), as well as in other clinical, endoscopic, and quality of life (QoL) outcomes, as shown by the results of the phase IIIB SEQUENCE trial presented at AIBD 2023.

Risankizumab superior to ustekinumab in severe CD

27 Dec 2023

Shifting to a plant-based diet may be key to better cardiometabolic health

27 Dec 2023 by

A systematic review and meta-analysis of prospective studies demonstrate that switching from animal-based (AB) to plant-based (PB) foods conferred cardiometabolic improvements.

Shifting to a plant-based diet may be key to better cardiometabolic health

27 Dec 2023

Minority healthcare workers more exposed to COVID-19‒related stressors

26 Dec 2023

Healthcare workers belonging to racial and ethnic minorities show greater exposure to several COVID-19‒related stressors, indicating a structural racism in the workforce, reports a study.

Minority healthcare workers more exposed to COVID-19‒related stressors

26 Dec 2023

Is histological remission feasible in UC patients?

26 Dec 2023 by

A study presented at AIBD 2023 provides strong evidence that histological remission may be achievable in patients with ulcerative colitis (UC).

Is histological remission feasible in UC patients?

26 Dec 2023

Adequately dosed racemic ketamine shots beneficial in treatment-resistant depression

25 Dec 2023

A 4-week course of racemic ketamine, when given by subcutaneous injection at adequate doses, appears to be safe and efficacious in people with treatment-resistant depression, according to a phase III trial.

Adequately dosed racemic ketamine shots beneficial in treatment-resistant depression

25 Dec 2023

Remdesivir shows no clear benefit in children with severe COVID-19

25 Dec 2023 by

The antiviral remdesivir offers no clear benefit in the treatment of children with severe COVID-19, falling short of reducing the time spent in high dependency or intensive care unit (HD/ICU), according to a study from Singapore.

Remdesivir shows no clear benefit in children with severe COVID-19

25 Dec 2023

Children resilient to early adversity at risk for anxiety, depression in adulthood

25 Dec 2023

It is not common to see children who have resilience to early adversity, and those who appear to be resilient in childhood are at increased risk of delayed poorer outcomes in adulthood, suggests a study.